Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Last modified by celine.gongora
Group name EquipeCG
Item Type Journal Article
Title Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study
Creator Houede et al.
Author N. Houede
Author E. Leutenegger
Author M. Lomma
Author C. Bellera
Abstract Cabazitaxel is a second line chemotherapy drug recently approved for the treatment of metastatic castration-resistant prostate cancer. A first panel of French experts and a second independent panel of European experts were convened to assess the conformity of prescription of cabazitaxel with a Delphi consensus method. A two-round modified Delphi consensus process was conducted. This methodology is based on experts' opinion obtained in a systematic manner. The process was divided into five steps: (i) elaboration of the questionnaire, (ii) rating, (iii) analysis, (iv) discussion of the points with absence of consensus following rating of the questionnaire, and (v) final reporting. Consensus was defined according to RAND method and all analyses were conducted according to the same methodology. At the end of the two rounds of rating and a synthesis meeting, of the 26 items included in the Summary of Product Characteristics (SPC), 11 items were judged appropriate with strong consensus by the two independent panels of experts. These items can therefore be considered of prime importance to evaluate conformity of cabazitaxel prescription in the context of observatory studies as well as in further clinical trials using this new taxane. Our findings further provide important evidence about the value of the Delphi consensus and highlight a requirement for "conformity" standards to assist practitioners in a safe chemotherapy drug prescription.
Publication PloS One
Volume 10
Pages e0123035
Date 2015
DOI 10.1371/journal.pone.0123035
ISSN 1932-6203 (Electronic) 1932-6203 (Linking)
Tags first, original
Date Added 2018/07/20 - 10:05:58
Date Modified 2019/10/24 - 16:15:33
Notes and Attachments (Note)
(Note)
25837603 (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés